Laboratory Medicine, Department of Clinical Chemistry, Saarland University Hospital, Building 57, D-66424 Homburg/Saar, Germany.
BioTeSys GmbH, Schelztorstr. 54-56, D-73728 Esslingen, Germany.
Nutrients. 2020 Nov 25;12(12):3623. doi: 10.3390/nu12123623.
(6S)-5-Methyltetrahydrofolic acid ((6S)-5-Methyl-THF) salts and folic acid may differ in their abilities to raise plasma (6S)-5-Methyl-THF levels. We compared the area under the curve (AUC), C, and T of plasma (6S)-5-Methyl-THF after intakes of (6S)-5-Methyl-THF-Na salt (Arcofolin) and folic acid. Moreover, we compared the AUCs after intakes of (6S)-5-Methyl-THF-Na and the calcium salt, (6S)-5-Methyl-THF-Ca, that were tested against folic acid in two independent studies. The study was randomized, double blind, and cross over. Twenty-four adults (12 men and 12 women) received a single oral dose of 436 µg (6S)-5-Methyl-THF-Na and an equimolar dose of folic acid (400 µg) on two kinetic days with two weeks washout period in between. The plasma concentrations of (6S)-5-Methyl-THF were measured at 9 time points between 0 and 8 h. We found that the AUC of plasma (6S)-5-Methyl-THF (mean (SD) = 126.0 (33.6) vs. 56.0 (25.3) nmol/L*h) and C (36.8 (10.8) vs. 11.1 (4.1) nmol/L) were higher after administration of (6S)-5-Methyl-THF-Na than after the administration of folic acid ( < 0.001 for both). These differences were present in men and women. Only administration of folic acid resulted in a transient increase in plasma unmetabolized folic acid (2.5 (2.0) nmol/L after 0.5 h and 4.7 (2.9) nmol/L after 1 h). Intake of (6S)-5-Methyl-THF-Na was safe. The ratios of the AUC for (6S)-5-Methyl-THF-Na and (6S)-5-Methyl-THF-Ca to the corresponding folic acid reference group and the delta of these AUC did not differ between the studies. In conclusion, a single oral dose of (6S)-5-Methyl-THF-Na caused higher AUC and C of plasma (6S)-5-Methyl-THF compared to folic acid. The Na- and Ca- salts of (6S)-5-Methyl-THF are not likely to differ in their pharmacokinetics. Further studies may investigate whether supplementation of the compounds for a longer time will lead to differences in circulating or intracellular/tissue folate concentrations.
(6S)-5-甲基四氢叶酸((6S)-5-甲基-THF)盐和叶酸在提高血浆(6S)-5-甲基-THF 水平的能力上可能存在差异。我们比较了(6S)-5-甲基-THF-Na 盐(Arcofolin)和叶酸摄入后的血浆(6S)-5-甲基-THF 的曲线下面积(AUC)、C 和 T。此外,我们比较了在两项独立研究中,(6S)-5-甲基-THF-Na 和钙盐(6S)-5-甲基-THF-Ca 与叶酸的 AUC。该研究是随机、双盲和交叉的。24 名成年人(12 名男性和 12 名女性)在两个动力学日分别服用 436µg(6S)-5-甲基-THF-Na 和等摩尔剂量的叶酸(400µg),两次之间有两周的洗脱期。在 0 至 8 小时之间的 9 个时间点测量血浆(6S)-5-甲基-THF 的浓度。我们发现,(6S)-5-甲基-THF 的 AUC(平均值(SD)=126.0(33.6)比 56.0(25.3)nmol/L*h)和 C(36.8(10.8)比 11.1(4.1)nmol/L)在(6S)-5-甲基-THF-Na 给药后高于叶酸给药后(均<0.001)。这些差异存在于男性和女性中。只有叶酸的摄入导致未代谢的叶酸在血浆中短暂增加(0.5 小时后为 2.5(2.0)nmol/L,1 小时后为 4.7(2.9)nmol/L)。(6S)-5-甲基-THF-Na 的摄入是安全的。(6S)-5-甲基-THF-Na 和(6S)-5-甲基-THF-Ca 的 AUC 与相应的叶酸参考组的比值以及这些 AUC 的差值在两项研究中没有差异。总之,单次口服(6S)-5-甲基-THF-Na 比叶酸引起的血浆(6S)-5-甲基-THF 的 AUC 和 C 更高。(6S)-5-甲基-THF 的 Na 和 Ca 盐在药代动力学方面可能没有差异。进一步的研究可能会调查这些化合物的补充时间是否会导致循环或细胞内/组织叶酸浓度的差异。